Sign in to view content

Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD

Robert L. Avery, MD

Video
Published 2021

Related

Wet AMD 7 Symposium
Annual Meeting Talks
2020
6-Month Results of a Phase 1b-2 Prospective Multicenter Clinical Trial of a Novel Targeted Therapy (AU-011) for the Treatment of Choroidal Melanoma
Amy C. Schefler, MD FACS FASRS
Annual Meeting Talks
2018
A Biocompatible Basal Membrane to Restore Age-Related Macular Degeneration Photoreceptor Damage
Stanislao Rizzo, MD
Annual Meeting Talks
2019

Category: AMD-Neovascular

See more